Developed and manufactured in Ireland, Aerogen Solo is built on our proprietary vibrating mesh technology and enables efficient aerosol drug delivery across multiple respiratory modalities. Its versatility has driven widespread adoption across U.S. hospitals, including intensive care units, emergency departments, neonatal care and transport settings.

The global scale of Aerogen Solo’s impact is both substantial and measurable. Aerogen’s aerosol drug delivery technology has been used to treat over 30 million patients worldwide and is trusted in more than 80 countries, including strong penetration within the U.S. acute care market, one of the world’s most demanding and clinically advanced environments.

Aerogen Solo addresses a critical healthcare challenge with significant economic implications: the effective, consistent and safe delivery of inhaled therapies for patients with acute and chronic respiratory compromise. Respiratory disease places a major burden on healthcare systems globally, including in the United States. Technologies that improve delivery efficiency, reduce treatment variability and standardise best practice support better patient outcomes while contributing to healthcare system efficiency and sustainability.

Aerogen is currently expanding its manufacturing capacity in Shannon, Ireland, investing in advanced equipment, duplicating production lines and qualifying additional suppliers. These investments strengthen supply chain resilience, reduce dependency risk for U.S. healthcare providers and ensure consistent availability for millions of patients worldwide. Continuous process optimisation and energy-efficient manufacturing reinforce sustainability while maintaining the highest quality and regulatory standards.

Aerogen Solo’s clinical and commercial impact is amplified through their global clinical education platform, delivered through integrated teams in Ireland and the United States. In 2025 alone, we educated over 50,000 clinicians globally, accelerating evidence-based adoption and embedding Aerogen Solo into routine clinical practice across ICU, emergency, neonatal and transport environments.

Importantly, Aerogen also functions as a platform technology for Aerogen Pharma, enabling collaboration with U.S.-based global health organisations, including the Bill & Melinda Gates Foundation. Through this partnership, Aerogen supports the development of inhaled pharmaceutical therapies designed to improve access to treatment in low- and middle-income countries. This work demonstrates how an Irish-manufactured technology, combined with U.S. global health investment and leadership, can extend its impact beyond commercial markets into public health and humanitarian settings.